Ryvu presented new preclinical proof-of-concept data for RVU602, our proprietary, potentially first-in-class ADC payload with a mechanism of action distinct from both TOPO1 and tubulin inhibitors.
🔗 Read more: lnkd.in/dU5N4v6P
Today, Agnieszka Ludwig-Słomczyńska will present new preclinical in vivo proof-of-concept data for RVU602 at World ADC 2026 in San Diego! Join her!
On September 29, Krzysztof Brzozka, CSO at Ryvu, will speak at the Drug Discovery Innovation Programme Europe 2026 in Basel.
If you are attending DDIP Europe, join the session and meet Krzysztof in Basel.
Aleksandra Sabiniarz, Director of Research Operations will represent Ryvu at the 25th Scientific Congress of the Polish Pharmaceutical Society in Wrocław, September 22-25. Ola will speak during the first plenary session. Learn more: ptfarmzjazd.pl/
Ryvu has signed a grant agreement with the National Centre for Research and Development. The agreement provides up to PLN 105.6 million in funding for the project “PANACEA-NOVO - patient-oriented innovative targeted therapies for rare cancers” lnkd.in/dr2v5YNj
Ryvu Therapeutics has reported its financial results for H1 2026 and provided an update on recent clinical and corporate progress.
Read the H1 2026 report: lnkd.in/eh7jb6QU
and the press release: lnkd.in/e4V8zD4H
On September 9-10, Karolina Osowska will attend the Oncology & Immunology Innovation Partnering & Licensing Summit. If you would like to discuss Ryvu’s oncology pipeline and partnering opportunities, connect with Karolina through the event’s one-to-one partnering portal.
Today, we are launching Keelira, our dedicated early clinical development services business for biotech and pharma companies seeking to extend oncology programs into Europe.
Read the press release: ryvu.com/press-release/ryvu-…
Learn more about Keelira: keelira.com
The MEDWAY project is moving forward, and we are proud to be part of it! The Children’s Memorial Health Institute officially launched a new investigator-initiated, non-commercial Phase I clinical study. More: ryvu.com/press-release/rvu12…
Thank you to Minister Pełczyńska-Nałęcz, Secretary of State Szyszko, and everyone from the Ministry of Development Funds and Regional Policy who joined us for an open and substantive conversation. We look forward to continuing this dialogue!
RyvuTx retweeted
Po raz pierwszy w historii powstaje lek wynaleziony i w całości opracowany przez naszych naukowców i naszą rodzimą firmę.
Tak warto budować rozwój.
Wsparte z KPO i Funduszy 🇪🇺🇵🇱
Ryvu Therapeutics and MENARINI Group have amended their global license agreement for #dapolsertib (MEN1703/SEL24).
Read more: lnkd.in/gVSaaDiv
We're headed to the BIO International Convention, June 22-25, in San Diego, CA! This year, you can find the Ryvu Therapeutics team: Vatnak Vat-Ho and Kamil Sitarz, PhD, MBA, at the PAIH – Polish Investment & Trade Agency booth #1411.
#BIO2026 #Partnering #RyvuTx
Już 12 czerwca o godz. 16:10 prof. Bozenna Dembowska-Bagińska przedstawi założenia projektu #MEDWAY podczas XIII Zjazdu PTOiHD w Gdańsku. Ryvu jest częścią tej inicjatywy!
O konferencji: lnkd.in/drbHHSr4
O projekcie MEDWAY: ryvu.com/pl/komunikat-prasow…
EHA 2026 is now underway, and our posters are available online.
Read more: lnkd.in/dGsdd5xj
View the posters: lnkd.in/dnmFMG8d
#RyvuTx #Romaciclib #EHA2026 #AML #Myelofibrosis #ClinicalResearch #Hematology
